Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

Adalimumab Biosimilar GP2017 Shows Similar Safety, Efficacy to Originator in Patients With IBD

December 5th 2023

By Cameron Santoro

Article

Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment.

BioRationality: Efficacy Testing and Interchangeability of Biosimilar Remains a Dogma for Most

December 4th 2023

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, comments on a poll he conducted revealing that many are still hesitant to remove clinical efficacy study requirements for biosimilars in his latest column.

Biosimilar Oncology Roundup for November 2023—Podcast Edition

December 3rd 2023

By Skylar Jeremias

Podcast

On this episode, we discuss the abundance of oncology news from November, especially during Global Biosimilars Week 2023, which was themed around the growth of oncology biosimilars.

Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions

December 2nd 2023

By Deana Ferreri, PhD

Article

A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.

The Top 5 Biosimilar Articles for the Week of November 27

December 1st 2023

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of November 27, 2023.

Biosimilars Oncology Roundup: November 2023

November 30th 2023

By Skylar Jeremias

Article

The Center for Biosimilars® covered an abundance of oncology news during November, especially during Global Biosimilars Week 2023, which was themed around the growth of oncology biosimilars.

IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity

November 29th 2023

By Skylar Jeremias

Article

A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.

HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain

November 28th 2023

By Skylar Jeremias

Article

Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.

CVS Caremark Switches Up Biosimilar Coverage in 2024

November 27th 2023

By Denise Myshko

Article

As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.

Dr Chelsee Jensen Discusses Pricing Strategies for Adalimumab Biosimilars

November 26th 2023

By Skylar Jeremias

Video

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, explains the purpose of dual-pricing strategies for adalimumab biosimilars and predicts whether these strategies will occur in other treatment spaces.